ASMB (Assembly Biosciences Inc) שולי הרווח הגולמי

ASMB (Assembly Corp) - סמל מסחרי של החברה

Assembly Biosciences develops innovative treatments for hepatitis B, leveraging the defensive nature of medical research that remains independent of macroeconomic trends. Gross profit margins demonstrate effective cost management amid Fed policy, with the indicator holding at 99.80. The company's profit stability will be fully solidified following the successful commercial launch of its drugs.

assemblybio.com (ASMB): שולי רווח גולמי מ-04.07.2022 עד 19.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Assembly Bio (ASMB)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
ניתוח מסכם של החברה:Assembly Biosciences, Inc. (ASMB)
מוצרים מוגמרים של Assembly Biosciences, Inc.

Gross margin measures direct production efficiency, determining the profit share of each unit of revenue after deducting variable costs. By analyzing historical gross margins, an investor assesses the pricing power of Assembly Biosciences (ASMB), which is based on the ownership of unique patents in hepatitis therapy, minimizing costs and cementing the long-term dependence of clinics on the company's proprietary drugs.